Elsevier

The Lancet

Volume 362, Issue 9378, 12 July 2003, Pages 126-128
The Lancet

Research Letters
Human monoclonal thyroid stimulating autoantibody

https://doi.org/10.1016/S0140-6736(03)13866-4Get rights and content

Summary

A monoclonal autoantibody (MAb) with powerful thyroid stimulating activity has been produced from lymphocytes from a patient with Graves' disease. The autoantibody and its Fab fragment bind to the thyroid stimulating hormone (TSH) receptor (TSHR) with high affinity, inhibit labelled TSH binding to the receptor and stimulate cyclic AMP production in Chinese hamster ovary cells transfected with TSHR. TSHR autoantibodies with TSH agonist or antagonist activities from patients' serum samples are effective inhibitors of labelled monoclonal autoantibody binding to TSHR. Thus, the human monoclonal autoantibody has all the characteristics of serum TSHR autoantibodies. Its availability has important implications for new studies on the pathogenesis of Graves' disease.

References (5)

  • B Rees Smith et al.

    Autoantibodies to the thyrotropin receptor

    Endocr Rev

    (1988)
  • SM McLachlan et al.

    Monoclonal, human autoantibodies to the TSH receptor-the holy grail and why are we looking for it?

    J Clin Endocrinol Metab

    (1996)
There are more references available in the full text version of this article.

Cited by (149)

View all citing articles on Scopus
View full text